Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Cash from Operations (2016 - 2021)

ENDRA Life Sciences (NDRA) has disclosed Cash from Operations for 6 consecutive years, with 2652726.0 as the latest value for Q4 2021.

  • Quarterly Cash from Operations fell 27.96% to 2652726.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was 11122384.0 through Dec 2021, down 3.5% year-over-year, with the annual reading at 5182558.0 for FY2025, 29.97% up from the prior year.
  • Cash from Operations for Q4 2021 was 2652726.0 at ENDRA Life Sciences, up from 2746763.0 in the prior quarter.
  • The five-year high for Cash from Operations was 236274.0 in Q1 2017, with the low at 3451665.0 in Q2 2020.
  • Average Cash from Operations over 5 years is 2073061.2, with a median of 2103281.5 recorded in 2020.
  • The sharpest move saw Cash from Operations plummeted 937.73% in 2018, then increased 18.9% in 2021.
  • Over 5 years, Cash from Operations stood at 1375584.0 in 2017, then plummeted by 38.3% to 1902427.0 in 2018, then decreased by 0.27% to 1907515.0 in 2019, then decreased by 8.68% to 2073106.0 in 2020, then decreased by 27.96% to 2652726.0 in 2021.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 2652726.0, 2746763.0, and 2799412.0 for Q4 2021, Q3 2021, and Q2 2021 respectively.